DAFTAR PUSTAKA

Akcay, S., Gurel Kandemir, N., Kaya, T., Dogan, N., & Eren, M. (2020). *Dextrose Prolotherapy Versus Normal Saline Injection for the Treatment of Lateral Epicondylopathy: A Randomized Controlled Trial. The Journal of Alternative and Complementary Medicine.* THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE. Vol 00(0), 2020, pp1–10.

Akpancar, S.; et. al.. (2019). *The effectiveness of prolotherapy on failed rotator cuff repair surgery. Turk J Phys Med Rehab* 2019;65(4):394-401 DOI: 10.5606/tftrd.2019.3222.

Altman, R. D., Devji, T., Bhandari, M., Fierlinger, A., Niazi, F., & Christensen, R. (2016). *Clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. Seminars in Arthritis and Rheumatism, 46(2), 151–159.* doi:10.1016/j.semarthrit.2016.04

Andarini, S. et al. (2019). *Factors Associated With Health Care Seeking Behavior for Musculoskeletal Pain in Indonesia: A Cross-Sectional Study. Wiley International Journal of Rheumatic Diseases. DOI: 10.1111/1756-185X.13536.* at: https://www.glycoforum.gr.jp/article/01A2.html [Accessed 30 November 2020].

Bakhsh, Wajeeh; Nicandri, Gregg (2018). Anatomy and Physical Examination of the Shoulder. Sports Medicine and Arthroscopy Review, 26(3), e10–e22. doi:10.1097/JSA.0000000000000202.

Bal, A., Eksioglu, E., Gulec, B., Aydog, E., Gurcay, E., & Cakci, A. (2008). *Effectiveness of corticosteroid injection in adhesive capsulitis. Clinical Rehabilitation, 22(6), 503–512.* doi:10.1177/0269215508086179

Bethan A. Brown, Helen Williams, Sarah J. George. Chapter Six - Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis, Progress in Molecular Biology and Translational Science, Academic Press, Volume 147, 2017, Pages 197-237, ISSN 1877-1173, ISBN

9780128116371, https://doi.org/10.1016/bs.pmbts.2017.01.004.Blain EJ. Mechanical regulation of matrix metalloproteinases. Front Biosci. 2007;12:507–27

Blaine, T., Moskowitz, R., Udell, J., Skyhar, M., Levin, R., Friedlander, J. Altman, R. (2008). *Treatment of Persistent Shoulder Pain with Sodium Hyaluronate: A Randomized, Controlled Trial. The Journal of Bone and Joint Surgery-American* Volume, 90(5), 970–979

Boumiza, S., Chahed, K., Tabka, Z. *et al.* MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity. *Sci Rep* **11**, 20052 (2021). https://doi.org/10.1038/s41598-021-99577-2

Brown IDM, Kelly IG, McInnes IB. Detection of matrix metalloproteinases in primary frozen shoulders. J Bone Joint Surg Br. 2008;90-B(Supp II):364.

Buchbinder, R. (2004). *Effect of arthrographic shoulder joint distension with saline and corticosteroid for adhesive capsulitis. British Journal of Sports Medicine, 38(4), 384–385.* doi:10.1136/bjsm.2004.013532

Cadogan, A., & Mohammed, K. D. (2016). *Shoulder pain in primary care: frozen shoulder. Journal of Primary Health Care, 8(1), 44.* doi:10.1071/hc15018.

Chang LR, Anand P, Varacallo M. Anatomy, Shoulder and Upper Limb, Glenohumeral Joint. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537018/

Chang R, Holcomb JB. Choice of Fluid Therapy in the Initial Management of Sepsis, Severe Sepsis, and Septic Shock. Shock. 2016 Jul;46(1):17-26.

Chidi-Ogbolu, N., & Baar, K. (2019). *Effect of Estrogen on Musculoskeletal Performance and Injury Risk. Frontiers in Physiology, 9.* doi:10.3389/fphys.2018.01834

Cho, C.-H., Song, K.-S., Kim, B.-S., Kim, D. H., & Lho, Y.-M. (2018). *Biological Aspect of Pathophysiology for Frozen*

Shoulder. *BioMed Research International, 2018, 1–8.* doi:10.1155/2018/7274517

Cohen C, Leal MF, Belangero PS, et al. The roles of Tenascin C and Fibronectin 1 in adhesive capsulitis: a pilot gene expression study. Clinics (Sao Paulo). 2016;71(6):325-331.

DeGroot J, Verzijl N, Wenting-van Wijk MJG, Bank RA, Lafeber FP, Bijlsma JW, et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated deg

Desai, A. S., Dramis, A., & Hearnden, A. J. (2010). *Critical appraisal of subjective outcome measures used in the assessment of shoulder disability. The Annals of The Royal College of Surgeons of England, 92(1), 9–13.* doi:10.1308/003588410x12518836440522

Diercks, R.L. & Stevens, M. (2004). *Gentle thawing of the frozen shoulder: a prospective study of supervised neglect versus intensive physical therapy in seventy-seven patients with frozen shoulder syndrome followed up for two years. J Shoulder Elbow Surg.* Sep. 2004;13(5):499-502.

Distel, L. M.; Best, T. M. 2011). *Prolotherapy: A Clinical Review of Its Role in Treating Chronic Musculoskeletal Pain. American Academy of Physical Medicine and Rehabilitation.* Vol. 3, S78-S81, June 2011. DOI: 10.1016/j.pmrj.2011.04.003.

Ecfeld, C; et. al.. (2019). *Functional disparities within the TIMP family in cancer: hints from molecular divergence. Cancer and Metastasis Reviews* https://doi.org/10.1007/s10555-019-09812-6.

Epstein EM, Waseem M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 10, 2021. Crystalloid Fluids.

Favejee, M. M., Huisstede, B. M. A., & Koes, B. W. (2010). *Frozen shoulder: the effectiveness of conservative and surgical interventions--systematic review. British Journal of Sports Medicine, 45(1), 49–56.* doi:10.1136/bjsm.2010.071431.

Green, S.; Buchbinder, R.; & Hetrick, S. (2003). *Physiotherapy interventions for shoulder pain.* Cochrane Database Syst Rev. 2003;(2):CD004258. doi: 10.1002/14651858.CD004258Harris, J. D.; Griesser, M. J.; Jones, L. J. (2011). *Treatment of*

adhesive capsulitis with intra-articular hyaluronate: A systematic review. *International Journal of Shoulder Surgery.* Apr-Jun 2011. Vol 5(2).

Hand, C., Clipsham, K., Rees, J. L., & Carr, A. J. (2008). *Long-term outcome of frozen shoulder. Journal of Shoulder and Elbow Surgery, 17(2), 231–236.* doi:10.1016/j.jse.2007.05.009

Hand, G. C. R., Athanasou, N. A., Matthews, T., & Carr, A. J. (2007). *The pathology of frozen shoulder. The Journal of Bone and Joint Surgery. British Volume, 89-B(7), 928–932.* doi:10.1302/0301-620x.89b7.19097.

Hascall, V. and Laurent, T., (1997). Glyco Forum. Hyaluronan: Structure and Physical Properties, [Online]. Vol 1, A2. Available

Hauser, Ross A.; Lackner, Johanna B.; Steilen-Matias, Danielle; Harris, David K. (2016). *A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 9(),* CMAMD.S39160–. doi:10.4137/CMAMD.S39160.

Hettrich, C. M. et. al.. (2016). *The effect of myofibroblasts and corticosteroid injections in adhesive capsulitis. . J Shoulder Elbow Surg.* doi.10.1016/j.jse.2016.01.012.

Hjermstad, M. J., Fayers, P. M., Haugen, D. F., Caraceni, A., Hanks, G. W., Loge, J. H., … Kaasa, S. (2011). *Studies Comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for Assessment of Pain Intensity in Adults: A Systematic Literature Review. Journal of Pain and Symptom Management, 41(6), 1073–1093.* doi:10.1016/j.jpainsymman.2010.0

Hubbard MJ, Hildebrand BA, Battafarano MM, Battafarano DF. (2018). Common Soft Tissue Musculoskeletal Pain Disorders. Prim Care. 45(2):289-303.

Itoi, E., Arce, G., Bain, G. I., Diercks, R. L., Guttmann, D., Imhoff, A. B., Yoo, Y.-S. (2016). *Shoulder Stiffness: Current Concepts and Concerns. Arthroscopy: The Journal of Arthroscopic & Related Surgery, 32(7), 1402–1414.* doi:10.1016/j.arthro.2016.03.024

Jahangiri, A., Moghaddam, F. R., & Najafi, S. (2014). *Hypertonic dextrose versus corticosteroid local injection for the treatment of osteoarthritis in the first carpometacarpal joint: a double-blind*

randomized clinical trial. *Journal of Orthopaedic Science, 19(5), 737–743.* doi:10.1007/s00776-014-0587-2

Kabbabe, B.; Ramkumar, S.; Richardson, M.; *Cytogenetic Analysis of Pathology of Frozen Shoulder. Int. Journal of Shoulder Surgery.*Vol.4(3), jul. 2010, p75-78.

Kim Y-S, Lee Y-G, Park H-S, Cho R-K, Lee H-J. Comparison of Gene Expression of Inflammation- and Fibrosis-Related Factors Between the Anterior and Posterior Capsule in Patients With Rotator Cuff Tear and Shoulder Stiffness. *Orthopaedic Journal of Sports Medicine.* 2021;9(10). doi:10.1177/23259671211032543

Kim, Y.-S., Kim, J.-M., Lee, Y.-G., Hong, O.-K., Kwon, H.-S., & Ji, J.-H. (2013). *Intercellular Adhesion Molecule-1 (ICAM-1, CD54) Is Increased in Adhesive Capsulitis. The Journal of Bone and Joint Surgery-American Volume, 95(4), e18–1– 8.* doi:10.2106/jbjs.k.00525.

Komosinska-Vassev, Katarzyna; Olczyk, Pawel; Winsz-Szczotka, Katarzyna; Kuznik-Trocha, Kornelia; Klimek, Katarzyna; Olczyk, Krystyna (2011). *Age- and Gender-Dependent Changes in Connective Tissue Remodeling: Physiological Differences in Circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 Level. Gerontology, 57(1), 44–52.* doi:10.1159/000295775

Kompel, A. J.; et al. (2019). *Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought? Radiology 2019*; 00:1–8 • https://doi.org/10.1148/radiol.2019190341.

Kostov K, Blazhev A. Changes in Serum Levels of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Essential Hypertension. Bioengineering (Basel). 2022 Mar 15;9(3):119. doi: 10.3390/bioengineering9030119. PMID: 35324807; PMCID: PMC8945798.

Kraal et al. (2020). *The puzzling pathophysiology of frozen shoulders – a scoping review.* Journal of Experimental Orthopaedics; 7:91 https://doi.org/10.1186/s40634-020-00307-w

Kyrtsonis, M. C.; et al. (1998). *Serum transforming growth factor- l is related to the degree of immunoparesis in patients with multiple rnyeioma. Medical Oncelogy.* 1998. vol 15: 124-128

Lee, J. H.; et al. (2015). *Effect of Hypertonic Saline in Intra-Articular Hydraulic Distension for Adhesive Capsulitis. American Academy of Physical Medicine and Rehabilitation.* http://dx.doi.org/10.1016/j.pmrj.2015.04.013

Lee, D.-H., Kwack, K.-S., Rah, U. W., & Yoon, S.-H. (2015). *Prolotherapy for Refractory Rotator Cuff Disease: Retrospective Case-Control Study of 1-Year Follow-Up. Archives of Physical Medicine and Rehabilitation, 96(11), 2027–2032.* doi:10.1016/j.apmr.2015.07.011

Le, H. V.; Lee, S. J.; Nazarian, A.; Rodriguez, E. K. (2016). *Adhesive capsulitis of the shoulder: review of pathophysiology and current clinical treatments. Shoulder & Elbow, (), 175857321 6676786–.* doi:10.1177/1758573216676786.

Lewis, Rececca. et al. (2019). *Strategies for Optimising Musculoskeletal Health in the 21th Century.* BMC Musculoskeletal Disorders (2019) 20:164 https://doi.org/10.1186/s12891-019-2510-7.

Lho Y-M, Ha E, Cho C-H, Song K-S, Min B-W, Bae K-C, Lee K-J, Hwang I, Park H-B (2013) Inflammatory cytokines are overexpressed in the subacromial bursa of frozen shoulder. J Shoulder Elb Surg 22:666–672.

Linaker, C. H., & Walker-Bone, K. (2015). *Shoulder disorders and occupation. Best Practice & Research Clinical Rheumatology, 29(3), 405–423.* doi:10.1016/j.berh.2015.04.001

Loveday, D., Johnston, P., Arthur, A., & Tytherleigh-Strong, G. (2009). *Frozen shoulder: a clinical review. British Journal of Hospital Medicine, 70(5), 276–278.*

Lowe, Dianne B.; Taylor, Michael J.; Hill, Sophie J. (2017). Associations between multimorbidity and additional burden for working-age adults with specific forms of musculoskeletal conditions: a cross-sectional study. BMC Musculoskeletal Disorders, 18(1), 135–.doi:10.1186/s12891-017-1496-2

Lubis, A. (2013). Matrix metalloproteinase, tissue inhibitor of metalloproteinase and transforming growth factor-beta 1 in frozen shoulder, and their changes as response to intensive stretching and supervised neglect exercise. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 18. doi : 10.1007/s00776-013-0387-0

Mandal M, Mandal A, Das S, Chakraborti T, Chakraborti S. *Clinical implications of matrix metalloproteinases.* Mol Cell Biochem. 2003;252:305–329.

Masuhara K, et al. 2002. *Significant Increases in Serum and Plasma Concentrasions of Matrix Metalloproteinases 3 and 9 in Patients With Rapidly Destructive Osteoarthritis of the Hip.* ARTHRITIS & RHEUMATISM Vol. 46, No. 10, October 2002, pp 2625–2631. DOI 10.1002/art.10547

Matta, C. & Mobasheri, A. (2014). *Regulation of chondrogenesis by protein kinase C: Emerging new roles in calcium signalling. Cellular Signalling.* 26 (2014) 979–1000.

Migliore, A (2015). *Effectiveness and utility of hyaluronic acid in osteoarthritis. Clinical Cases in Mineral and Bone Metabolism, (), –.* doi:10.11138/ccmbm/2015.12.1.031

Nicholson, G. P. (2003). *Arthroscopic Capsular Release for Stiff Shoulders: Effect of Etiology on Outcomes. Arthroscopy: The Journal of Arthroscopic and Related Surgery,* Vol 19(1) January 2003: pp 40-49

Oh, J. H.; et. al.. (2011). *Comparison of glenohumeral and subacromial steroid injection in primary frozen shoulder: a prospective, randomized short-term comparison study.* J Shoulder Elbow Surg (2011) 20, 1034-1040.

Ongley, M., Dorman, T., Klein, R., Eek, B., & Hubert, L. (1987). *A NEW APPROACH TO THE TREATMENT OF CHRONIC LOW BACK PAIN. The Lancet, 330(8551), 143–146.* doi:10.1016/s0140-6736(87)92340-3

Oosterwijk, A.M.; Nieuwenhuis, M.K; van der Schans,C.P.; & Mouton, L.J. va(2018). *Shoulder and elbow range of motion for the performance of activities of daily living: A systematic review, Physiotherapy Theory and Practice,* DOI: 10.1080/09593985.2017.1422206

Patanwala, A. E.; Amini, A.; Erstad, B. L. (2010). *Use of hypertonic saline injection in trauma. Am J Health-Syst Pharm.* Vol 67 Nov 15, 2010. DOI 10.2146/ajhp090523.

Prodromidis, A. D.; Charalambous, C. P. (2016). Is There a Genetic Predisposition to Frozen Shoulder?: A Systematic Review and

Meta-Analysis. JBJS Reviews, 4(2), e4–e4. doi:10.2106/JBJS.RVW.O.00007.

Rabago, D. et al. (2019). *Prolotherapy for Musculoskeletal Pain and Disability in Low- and Middll-Income Countries.* Phys Med Rehabil Clin N Am 30 (2019) 775–786 https://doi.org/10.1016/j.pmr.2019.07.003.

RISKESDAS. Riskesdas 2018. Jakarta Badan Penelit dan Pengemb Kesehat Dep Kesehat Republik Indones [Internet]. https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf

Robinson, C. M.; Seah, K. T. M.; Chee, Y. H.; Hindle, P.; Murray, I. R..(2012). *Frozen shoulder. , 94 b(1), 1–9.* doi:10.1302/0301-620x.94b1.27093.

Rodeo, S. A.; et al. (199). *Immunolocalization of Cytokines and their Receptors in Adhesive Capsulitis of the Shoulder. Jorrrnul of Orthopaedic Research* vol. 15:p427-436.

Roy, J.-S., MacDermid, J. C., & Woodhouse, L. J. (2009). *Measuring shoulder function: A systematic review of four questionnaires. Arthritis & Rheumatism, 61(5), 623–632.* doi:10.1002/art.24396

Saltzman, B. M., Leroux, T., Meyer, M. A., Basques, B. A., Chahal, J., Bach, B. R., … Cole, B. J. (2016). *The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. The American Journal of Sports Medicine, 45(11), 2647–2653.* doi:10.1177/0363546516680607

Sam N, Yusuf I, Idris I, Adnan E, Haryadi RD, Hamid F, Usman MA, Johan MP, Zainuddin AA, Bukhari A. Effectiveness of Prolotherapy Combined with Physical Therapy Versus Physical Therapy Only for Frozen Shoulder: A Case Report. Am J Case Rep. 2022 Oct 12;23:e936995. doi: 10.12659/AJCR.936995. PMID: 36223329.

Sebbag, Eden et al. (2019). *The World-Wide Burden of Musculoskeletal Disease: a Systemic Analysis of the World Health Organization Burden of Diseases Database.* Ann Rheum Dis 2019;0:1–5. doi:10.1136/annrheumdis-2019-21514

Shah, Nicholas. (2007). *Shoulder adhesive capsulitis: systematic review of randomised trials using multiple corticosteroid injections.* <u>Br J Gen Pract</u>. 57(541): 662–667.

Sumarwoto T, Hadinoto SA, Roshada MF. Frozen Shoulder: Current Concept of Management. Open Access Maced J Med Sci. 2021 Mar 01; 9(F):58-66. https://doi.org/10.3889/oamjms.2021.5716

Sung CM, Tae Sik Jung, Park H Bin (2014). *Are serum lipids involved in primary frozen shoulder?.* Jbjs 96-A:1828–1833.

Trescot, A. (2016). *Everything old is new again: New developments in prolotherapy. Techniqu in Regional Anasthesi and Pain Management.* http://dx.doi.org/10.1053/j.trap.2016.09.003.

UK Biobank. 2011. *Blood Sample Collection, Processing and Transport version 01.* https://www.ukbiobank.ac.uk/

Ulrich D, Hrynyschyn K, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast Reconstr Surg. 2003 Oct;112(5):1279-86. doi: 10.1097/01.PRS.0000081462.40448.49. PMID: 14504511.

Ulrich D, Lichtenegger F, Eblenkamp M, Repper D, Pallua N. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with trilucent breast implants. Plast Reconstr Surg. 2004;114:229–36.

Van der Windt, D. A. W. M.; Koes, B. W.; Devillé W.; Boeke, A. J. P.; de Jong, B. A.; Bouter, L. M. (1998). *Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ.* Nov. 1998. 7;317(7168):1292-6. doi: 10.1136/bmj.317.7168.1292.

Vaught JB, Henderson MK. Biological sample collection, processing, storage and information management. IARC Sci Publ. 2011;(163):23-42.

Waluyo, Y., Budu, Bukhari, A., Adnan, E., Darjanti Haryadi, R., Idris, I., Hamid, F., Usman, A., Johan, M. P., & Zainuddin, A. A. (2021). *Changes in levels of cartilage oligomeric proteinase and*

urinary C-terminal telopeptide of type II collagen in subjects with knee osteoarthritis after dextrose prolotherapy: A randomized controlled trial. Journal of Rehabilitation Medicine, 53(5). https://doi.org/10.2340/16501977-2835.

Wang xi and Khalil, R. A. (2018). Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol . 2018 ; 81: 241–330. doi:10.1016/bs.apha.2017.08.002.

Wang ED, Badalamente MA, Mackenzie S, et al. Phase 2a Study of Safety/Efficacy of Collagenase (CCH) in Patients with Adhesive Capsulitis: Level 2 Evidence. Paper presented at American Society for Surgery of the Hand annual meeting, September 2015; Seattle, WA.

Wu, T.J.; et al. (2018). Glucose enhances aggrecan expression in chondrocytes via the PKCα/p38 miR141-3p signaling pathway. Journal of Cellular Physiology. I DOI 10.1002/jcp.26451.

Wylie, James D (2014). Functional outcomes assessment in shoulder surgery. World Journal of Orthopedics, 5(5), 623– . doi:10.5312/wjo.v5.i5.623

Yoshii, Y. (2014). Effects of multiple injections of hypertonic dextrose in the rabbit carpal tunnel: a potential model of carpal tunnel syndrome development. American Association for Hand Surgery. (2014) 9:52–57. DOI 10.1007/s11552-013-9599-1.

Zuckerman, J. D.; Andrew Rokito (2011). Frozen shoulder: a consensus definition. , 20(2), 0–325. doi:10.1016/j.jse.2010.07.008

LAMPIRAN-LAMPIRAN

Lampiran I

LEMBAR PENJELASAN SEBELUM TINDAKAN

NASKAH PENJELASAN UNTUK RESPONDEN

Assalamu'alaikum warahmatullahi wabarakatuh

Salam sejahtera teriring doa semoga segala aktivitas keseharian kita mendapat rahmat dan ridho Allah SWT. Saya dr. Nuralam Sam, Sp.KFR yang akan melakukan penelitian tentang **KADAR *MATRIX METALLOPROTEINASE-1 (*MMP-1) DAN *TISSUE INHIBITOR MATRIX METALLOPROTEINASE*-1 (TIMP-1) SETELAH INTERVENSI PROLOTERAPI DAN *OUTCOME* FUNGSIONAL PADA PASIEN DENGAN *FROZEN SHOULDER***, kami bermaksud ingin mengikutsertakan anda sebagai subyek pada penelitian ini.

Penelitian ini bertujuan untuk mengetahui efek pemberian larutan glukosa pada sendi pasien penderita FS khususnya di Klinik Cerebellum, Makassar. Penelitian ini diharapkan dapat memberikan rekomendasi tentang terapi utama penyakit FS.

Adapun prosedur yang akan dilaksanakan pada penelitian ini yaitu :

1. Wawancara dan pemeriksaan fisik

   Pertanyaan yang akan diajukan saat wawancara adalah identitas pasien, derajat keparahan gejala yang dialami terkait dengan osteoartritis, skor fungsional dan riwayat pengobatan. Pemeriksaan fisik dan penunjang yang dilakukan berupa berat dan tinggi badan serta keadaan lokalis bahu. Pemeriksaan skor fungsional akan

diulangi di minggu ke-6 dan minggu ke-12 pada intervensi proloterapi

menggunakan dextrose dan normal salin

2. Pemeriksaan radiologi

Foto thorax dada dilakukan untuk untuk menilai penyebab sindrom

FS sekunder, seperti tumor tulang, deposit atau fraktur kalsifikasi

akut (jika ada riwayat trauma).

3. Pengambilan sampel darah

Pengambilan sampel darah dilakukan untuk mengetahui kadar

MMP-1 dan TIMP-1. Prosedur pengambilan darah disesuaikan

dengan prosedur operasional yang terstandarisasi (SOP).

Pengambilan darah akan dilakukan pada hari ke-1, dan minggu ke-

8 untuk subyek dengan intervensi proloterapi menggunakan larutan

dextrose dan normal saline.

4. Pemberian intervensi

Pemberian proloterapi akan dilakukan dengan cara menyuntikkan

larutan glukosa pada sendi bahu subyek yang disesuaikan dengan

SOP. Pemberian proloterapi dilakukan pada hari ke-1 minggu ke-0

dan minggu ke-4.

Pemberian larutan dextrose dan normal saline akan dilakukan

dengan cara menyuntikkan Adant® dispo pada sendi bahu subyek

yang disesuaikan dengan SOP.

Biaya penelitian ini akan ditanggung oleh dokter yang melakukan

penelitian dan tidak dibebankan pada anda. Kami menjamin kerahasiaan

semua data pada penelitian ini. Data penelitian ini akan dikumpulkan dan disimpan tanpa menyebutkan nama anda dan disimpan dalam arsip tertulis atau elektronik yang hanya dapat dilihat oleh penliti dan tim peneliti dari Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Hasanuddin. Semua hasil pemeriksaan yang terkait dengan penelitian ini akan disampaikan kepada anda secara terbuka. Hasil penelitian ini nantinya akan dipublikasikan pada publikasi ilmiah, namun kami akan merahasiakan kerahasiaan identitas anda.

Kami sangat mengharapkan partisipasi anda, dengan bersedia untuk ikut dalam penelitian ini secara sukarela. Bila anda bersedia, kami berharap anda dapat memberikan persetujuan dalam bentuk lisan dan tertulis.

Bila anda merasa masih ada yang belum jelas atau belum dimengerti dengan baik, anda dapat menanyakan atau minta penjelasan pada saya.

Identitas Peneliti : dr. Nuralam Sam, Sp.KFR

Alamat :

> **DISETUJUI OLEH KOMISI ETIK PENELITIAN KESEHATAN FAK. KEDOKTERAN UNHAS**
>
> **Tgl. …………….....**

Lampiran II

<p align="center">LEMBAR PERSETUJUAN RESPONDEN</p>
<p align="center">SURAT PERSETUJUAN MENGIKUTI PENELITIAN</p>

Yang bertandatangan di bawah ini

Nama   : ....

Umur   : ....

Alamat   : ....

Pekerjaan   : ....

     Dengan ini menyatakan bahwa setelah saya mendapatkan penjelasan, telah diberi kesempatan bertanya, dan pertanyaan saya telah terjawab sepenuhnya dengan jelas serta saya telah memahami sepenuhnya maksud dan tujuan penelitian yang berjudul:

<p align="center">"KADAR MATRIX METALLOPROTEINASE-1 (MMP-1) dan TISSUE INHIBITOR MATRIX METALLOPROTEINASE-1 (TIMP-1) SETELAH INTERVENSI PROLOTERAPI DAN OUTCOME FUNGSIONAL PADA PASIEN DENGAN FROZEN SHOULDER"</p>

     Maka saya menyatakan **SETUJU** untuk ikut serta dalam penelitian ini, bersedia dan tidak keberatan mematuhi semua ketentuan yang berlaku dalam penelitian ini, dan memberikan keterangan yang sebenarnya.

     Demikian pernyataan ini saya buat dalam keadaan sadar dan tanpa paksaan untuk digunakan sebagaimana mestinya.

NAMA	**TANDA TANGAN**	**TANGGAL**
Klien	....	....
Saksi	....	....

Identitas Peneliti
Nama   **:** dr. Nuralam Sam, Sp.KFR
Alamat   **:**
No. HP   **:**

Penanggung Jawab Medik
Nama   **:**
Alamat   **:**
No. HP   **:**

Lampiran III

KADAR *MATRIX METALLOPROTEINASE-1 (*MMP-1) DAN *TISSUE INHIBITOR MATRIX METALLOPROTEINASE*-1 (TIMP-1) SETELAH INTERVENSI PROLOTERAPI DAN *OUTCOME* FUNGSIONAL PADA PASIEN DENGAN *FROZEN SHOULDER*

Tanggal pengambilan data : ……../……../ 2021

A. IDENTITAS RESPONDEN

1. Nama responden   : …………………………………………………
2. Tanggal lahir   : …………………………………………………
3. Nomor rekam medik   : …………………………………………………
4. Alamat lengkap   : …………………………………………………
5. Nomor telepon   : …………………………………………………
6. Paritas   : G   P   A
7. Agama   : Islam / Kristen / Katolik / Budha / Hindu
8. Pendidikan   : Tidak sekolah / SD / SMP / SMA / PT
9. Pekerjaan   : Bekerja / tidak bekerja
10. Jenis kontrasepsi   : Implant / DMPA

B. RIWAYAT RESPONDEN

1) Lama menderita FS   : .... tahun
2) Bukti klinis FS   : Hasil foto Ro/ hasil laboratorium
3) Keluhan yang dialami selama FS   : ……………………………………
4) Skor VAS   : ……………………………………
5) Riwayat penyakit lain yang pernah diderita: ……………………………
6) Riwayat perawatan di rumah sakit : ……………………………………
7) Riwayat terapi terkait FS   : ……………………………………
8) Riwayat mengkonsumsi obat-obatan rutin: ………………………………
9) Perilaku kesehatan   : merokok/alkohol
                                      Pola diet
                                      Aktivitas fisik
                                      Pola istirahat

C. HASIL PEMERIKSAAN FISIK DAN PENUNJANG

1) Berat Badan   : ………………………………
2) Tinggi Badan   : ………………………………
3) Indeks Massa Tubuh   : ………………………………
4) Kadar MMP-1 Awal   : ………………………………
5) Kadar TIMP-1 Awal   : ………………………………
6) Pemeriksaan Lab Lainnya: ………………………………

PEMERIKSA

(_____)

KUESIONER SKOR THE DISABILITIES OF THE ARM, SHOULDER AND HAND (DASH)

Berikan penilaian terhadap kemampuan anda dalam melakukan aktivitas berikut selama satu minggu terakhir.

1. Membuka tutup toples	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
2. Menulis	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
3. Memutar kunci	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
4. Menyiapkan makanan	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
5. Mendorong pintu	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
6. Menempatkan benda di atas kepala	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
7. Melakukan pekerjaan rumah tangga yang berat (membersihkan dinding, membersihkan lantai)	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
8. Berkebun atau membersihkan halaman	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
9. Merapikan tempat tidur	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
10. Membawa tas belanja atau tas kerja	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
11. Membawa benda berat (>10 pound)	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
12. Mengganti bola lampu	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
13. Mencuci atau mengeringkan rambut	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
14. Membersihkan daerah punggung	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
15. Mengenakan sweater	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
16. Menggunakan pisau untuk memotong makanan	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
17. Aktivitas yang membutuhkan tenaga (bermain kartu, merajut, dsb)	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
18. Aktivitas yang membutuhkan tenaga atau berdampak pada lengan, bahu dan tangan (golf, tennis, dsb)	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
19. Aktivitas yang mengayunkan lengan dengan bebas (*frisbee*, bulu tangkis, dsb)	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
20. Mampu berkendara (berpindah dari satu tempat ke tempat lain)	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
21. Aktivitas seksual	Tidak Sulit	Agak Sulit	Sulit	Sangat Sulit	Tidak Mampu
22. Selama seminggu terakhir, sejauh mana masalah lengan, bahu, atau tangan Anda mengganggu aktivitas sosial normal Anda dengan keluarga, teman, tetangga, atau kelompok?	Tidak Sama Sekali	Sedikit	Cukup	Lumayan	Sangat
23. Selama seminggu terakhir, apakah pekerjaan atau aktivitas anda sehari-hari terganggu akibat masalah pada lengan, bahu dan tangan?	Tidak Terbatas Sama Sekali	Sedikit Terbatas	Cukup Terbatas	Sangat Terbatas	Tidak Mampu

Beri penilaian terhadap derajat keparahan gejala yang timbul selama satu minggu terakhir.

24. Nyeri pada lengan, bahu dan tangan	Tidak Ada	Ringan	Sedang	Berat	Ekstrim
25. Nyeri pada lengan, bahu dan tangan pada saat digunakan	Tidak Ada	Ringan	Sedang	Berat	Ekstrim
26. Rasa kesemutan pada lengan, bahu dan tangan	Tidak Ada	Ringan	Sedang	Berat	Ekstrim

27. Lemah pada pada lengan, bahu dan tangan	Tidak Ada	Ringan	Sedang	Berat	Ekstrim
28. Terasa kaku pada lengan, bahu dan tangan	Tidak Ada	Ringan	Sedang	Berat	Ekstrim
29. Selama seminggu terakhir, seberapa sulit anda dapat tidur akibat nyeri pada lengan, bahu dan tangan	Tidak Sulit	Ringan	Sedang	Berat	Tidak dapat Tidur
30. Saya merasa kurang mampu, kurang percaya diri atau kurang berguna karena masalah lengan, bahu, atau tangan saya	Sangat Tidak Setuju	Tidak Setuju	Tidak Yakin (Ragu)	Setuju	Sangat Setuju

Total Skor DASH	Interpretasi	Keterangan
0-20%	Ringan	Pasien dapat melakukan aktivitas kesehariannya
21-40%	Sedang	Pasien merasa sakit dan mengalami kesulitan duduk, mengangkat barang. Kehidupan pribadi tidak terganggu
41-60%	Berat	Pasien masih merasa nyeri dan kehidupan pribadi terganggu
61-80%	Sangat Berat	Nyeri pasien sudah mengganggu seluruh aktivitas hidupnya dan butuh intervensi medis
81-100%		Pasien tidak bisa beranjak dari tempat tidurnya

Interpretasi Skor DASH

Perhitungan skoring:

DASH disability/symptom score = [(sum of n responses) - 1] x 25

https://www.dash.iwh.on.ca/sites/dash/files/downloads/dash_scoring_2010.pdf

Lampiran V

TEKNIK PENGAMBILAN DARAH VENA

Venipuncture
For use with vacutainer tubes

Always use universal safety precautions.

1. Collect supplies.

2. Label tube with the client identification number.

3. Put tourniquet on client about 3-4" above venipuncture site.

4. Have client form a fist so veins are more prominent.

5. After palpating the path of the vein, clean the venipuncture site with alcohol using a circular motion. Allow the area to dry.

6. Assemble needle and vacuum tube holder.

7. Insert the collection tube into the holder until the tube reaches the needle.

8. Remove cap from needle.

9. Use your thumb to draw skin tight about 1- 2" below the venipuncture site. Hold skin tight through Step 10.

10. Insert the needle, bevel side up, into the vein.

11. Push the vacutainer tube completely onto the needle. Blood should begin to flow into the tube.

12. Release the tourniquet.

13. Fill the tube until it is full or until vacuum is exhausted.

14. After opening client's hand, place dry gauze over the venipuncture site.

15. Apply mild pressure to the pad and slowly remove the needle.

16. Apply bandage or continue applying mild pressure until bleeding has stopped.

17. Properly dispose of all contaminated supplies.

Lampiran VI

TEKNIK MOBILISASI SAMPEL

10.12.6: Waste disposal

The laboratory area is kept clean, and documents are maintained for each cleaning routine undertaken. All hazardous waste bins are emptied and the secured bags taken to the hazardous waste collection bin. Documents are maintained describing whether they are sharps, bags or urine containers. The documents describing the clinical waste totals are sent to the co-ordinating centre support team on the last working day of each month.

11.   Transporting of samples

11.1: This section details the correct method of packing the blood, urine and saliva samples so they reach the UK Biobank laboratory undamaged and within acceptable temperature limits. Also detailed are the correct method for dealing with courier pick ups, any delays in pick up and the return of sample boxes from UK Biobank Coordinating Centre.

11.2: Preparing samples for transport

At the beginning of each day the lab processing staff member prepares 12 transport racks: 8 for the blood and urine tubes and 4 for the saliva tubes. These are stored in the Assessment Centre holding fridge, except for the ACD blood sample tubes – yellow cap. During the day the sample tubes are loaded into the specific transport rack from the first participant to the last participant (Figure 5). The ACD blood sample tubes are kept AND transported at room temperature in a rack.

Figure 5: Transport rack

11.3: The EDTA 4ml (small) tube (purple cap) and the ACD tubes have a smaller inner rack within the transport rack to ensure the smaller tubes are transported safely.

11.4: 45 minutes prior to the courier arriving, lids are placed on the racks and each rack is individually placed inside a plastic bag. Three sheets of absorbent paper are placed inside the bag. The plastic bag is sealed with a cable tie (figure 6).

Figure 6: Sealing racks for transport

11.5: On the two short sides of the transport box are placed a cool pack and a spacer (see figure 7). The cool packs are kept in the freezer for at least 24 hours before use and are taken out 30 minutes before being used each day.

Figure 7: Mediporter transport box with cool packs

11.6: The bagged racks (except the ACD tubes) are placed into the large transport box (figure 8).

Figure 8: Racks in Mediporter

11.7: A third spacer is placed on top once the sample racks are all loaded and the

21

third cool pack is placed on top of the spacer (figure 9).

Figure 9: Mediporter with cool pack

11.8: The polystyrene lid is placed on top of the box. The lid of the plastic outer box is closed. Every Tuesday a datalogger is placed in both the large transport box and the Mediporter **(Section 13)**.

11.9: The ACD samples are placed inside a Mediporter without a cool pack

11.10: The lids of both transport boxes are closed and sealed with plain cable ties (figure 10) and they are moved to the designated pick up area.

Figure 10: Sealing the transport boxes

12.   Courier collection

12.1: All Assessment Centres use TNT to return the sample transport boxes to the Co-ordinating Centre Laboratory. Collections from all Assessment Centres occur at 8:30pm, Monday to Saturday (excluding Bank Holidays).

12.2: The sample transport boxes are packed (Section 11) and placed ready for collection in a designated area. TNT provide all UK Biobank Assessment Centres with pre-addressed consignment notes. Assessment Centre Staff complete a TNT Consignment note by inserting the date, and then attaching a barcode from the consignment note on to each individual transport box, prior to collection. Transport boxes are made ready for collection before 8:30pm.

22

Lampiran VII

PROTOKOL PEMERIKSAAN MMP-1

Assay Procedure

1. Prepare all reagents, standard solutions and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature.

2. Determine the number of strips required for the assay. Insert the strips in the frames for use. The unused strips should be stored at 2-8°C.

3. Add 50µl standard to standard well. **Note**: Don't add antibody to standard well because the standard solution contains biotinylated antibody.

4. Add 40µl sample to sample wells and then add 10µl anti-MMP-1 antibody to sample wells, then add 50µl streptavidin-HRP to sample wells and standard wells (Not blank control well). Mix well. Cover the plate with a sealer. Incubate 60 minutes at 37°C.

5. Remove the sealer and wash the plate 5 times with wash buffer. Soak wells with at least 0.35 ml wash buffer for 30 seconds to 1 minute for each wash. For automated washing, aspirate all wells and wash 5 times with wash buffer, overfilling wells with wash buffer. Blot the plate onto paper towels or other absorbent material.

6. Add 50µl substrate solution A to each well and then add 50µl substrate solution B to each well. Incubate plate covered with a new sealer for 10 minutes at 37°C in the dark.

7. Add 50µl Stop Solution to each well, the blue color will change into yellow immediately.

8. Determine the optical density (OD value) of each well immediately using a microplate reader set to 450 nm within 10 minuets after adding the stop solution.

Lampiran VIII
PROTOKOL PEMERIKSAAN TIMP-1

Assay Procedure

1. Prepare all reagents, standard solutions and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature.

2. Determine the number of strips required for the assay. Insert the strips in the frames for use. The unused strips should be stored at 2-8°C.

3. Add 50μl standard to standard well. **Note**: Don't add antibody to standard well because the standard solution contains biotinylated antibody.

4. Add 40μl sample to sample wells and then add 10μl anti-TIMP-1 antibody to sample wells, then add 50μl streptavidin-HRP to sample wells and standard wells (Not blank control well). Mix well. Cover the plate with a sealer. Incubate 60 minutes at 37°C.

5. Remove the sealer and wash the plate 5 times with wash buffer. Soak wells with at least 0.35 ml wash buffer for 30 seconds to 1 minute for each wash. For automated washing, aspirate all wells and wash 5 times with wash buffer, overfilling wells with wash buffer. Blot the plate onto paper towels or other absorbent material.

6. Add 50μl substrate solution A to each well and then add 50μl substrate solution B to each well. Incubate plate covered with a new sealer for 10 minutes at 37°C in the dark.

7. Add 50μl Stop Solution to each well, the blue color will change into yellow immediately.

8. Determine the optical density (OD value) of each well immediately using a microplate reader set to 450 nm within 10 minuets after adding the stop solution.

Lampiran IX

DUMMY TABLE
RANCANGAN TABEL HASIL OLAH DATA

1. Karakteristik subyek

KARAKTERISTIK SUBYEK	N	%
Jenis Kelamin - Laki-laki - Perempuan		
Usia - <30 tahun - 30-50 tahun - >50 tahun		
Pekerjaan - PNS - Karyawan swasta - Dll		
Pendidikan - <SMA - Sarjana - Pascasarjana		
Riwayat FS - <5 tahun - 5-10 tahun - >10 tahun		
Riwayat terapi - Farmakologi - Non-farmakologi		
Status IMT - Gizi Kurang - Gizi cukup - Gizi lebih - Obesitas		

2. Perbandingan kadar MMP-1 sebelum dan sesudah intervensi proloterapi

NOMOR RESPONDEN	KADAR MMP-1		KETERANGAN
	SEBELUM PROLOTERAPI	SETELAH PROLOTERAPI	
PERLAKUAN 1			Kadar meningkat/ tetap/menurun
PERLAKUAN 2			
PERLAKUAN 3			
PERLAKUAN 4			

3. Perbandingan kadar TIMP-1 sebelum dan sesudah intervensi proloterapi

NOMOR RESPONDEN	KADAR TIMP-1		KETERANGAN
	SEBELUM PROLOTERAPI	SETELAH PROLOTERAPI	
PERLAKUAN 1			Kadar meningkat/ tetap/menurun
PERLAKUAN 2			
PERLAKUAN 3			
PERLAKUAN 4			

Lampiran X

1. Tabel Data Karakteristik

Descriptive Statistics

	N	Minimum	Maximum	Sum	Mean		Std. Deviation
	Statistic	Statistic	Statistic	Statistic	Statistic	Std. Error	Statistic
Umur	39	40	78	2257	57,87	1,400	8,742
Tinggi Badan	39	150	180	6261	160,54	1,398	8,729
Berat Badan	39	43,00	89,00	2367,00	60,6923	1,77292	11,07190
IMT	39	16,33	29,14	915,29	23,4689	0,51948	3,24413
GDS Pre Injeksi	39	40	430	5985	153,46	12,025	75,095
GDS Post Injeksi	39	77	387	6079	155,87	11,109	69,376
Kolesterol	39	127	350	8180	209,74	8,418	52,570
Asam Urat	39	3,2	72,0	604,7	15,505	3,1170	19,4655
Valid N (listwise)	39						

Crosstab

			Jenis kelamin		
			Pria	Wanita	Total
Jenis Sampel	Prolo	Count	6	13	19
		% within Jenis Sampel	31,6%	68,4%	100,0%
		% within Jenis kelamin	40,0%	54,2%	48,7%
		% of Total	15,4%	33,3%	48,7%

Normal Saline	Count	9	11	20	
	% within Jenis Sampel	45,0%	55,0%	100,0%	
	% within Jenis kelamin	60,0%	45,8%	51,3%	
	% of Total	23,1%	28,2%	51,3%	
Total	Count	15	24	39	
	% within Jenis Sampel	38,5%	61,5%	100,0%	
	% within Jenis kelamin	100,0%	100,0%	100,0%	
	% of Total	38,5%	61,5%	100,0%	

Crosstab

			Pekerjaan						Total
			Guru	IRT	Pensiunan	PNS	Polisi	Wiraswasta	
Jenis Sampel	Prolo	Count	3	7	3	4	0	2	19
		% within Jenis Sampel	15,8%	36,8%	15,8%	21,1%	0,0%	10,5%	100,0%
		% within Pekerjaan	42,9%	53,8%	50,0%	66,7%	0,0%	33,3%	48,7%
		% of Total	7,7%	17,9%	7,7%	10,3%	0,0%	5,1%	48,7%
	Normal Saline	Count	4	6	3	2	1	4	20
		% within Jenis Sampel	20,0%	30,0%	15,0%	10,0%	5,0%	20,0%	100,0%
		% within Pekerjaan	57,1%	46,2%	50,0%	33,3%	100,0%	66,7%	51,3%
		% of Total	10,3%	15,4%	7,7%	5,1%	2,6%	10,3%	51,3%

Total	Count	7	13	6	6	1	6	39
	% within Jenis Sampel	17,9%	33,3%	15,4%	15,4%	2,6%	15,4%	100,0%
	% within Pekerjaan	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%
	% of Total	17,9%	33,3%	15,4%	15,4%	2,6%	15,4%	100,0%

Crosstab

			Agama			
			Islam	Katolik	Kristen	Total
Jenis Sampel	Prolo	Count	18	1	0	19
		% within Jenis Sampel	94,7%	5,3%	0,0%	100,0%
		% within Agama	50,0%	100,0%	0,0%	48,7%
		% of Total	46,2%	2,6%	0,0%	48,7%
	Normal Saline	Count	18	0	2	20
		% within Jenis Sampel	90,0%	0,0%	10,0%	100,0%
		% within Agama	50,0%	0,0%	100,0%	51,3%
		% of Total	46,2%	0,0%	5,1%	51,3%
Total		Count	36	1	2	39
		% within Jenis Sampel	92,3%	2,6%	5,1%	100,0%
		% within Agama	100,0%	100,0%	100,0%	100,0%

124

Crosstab

			Pendidikan					Total
			S1	SD	SMA	SMP	tidak sekolah	
Jenis Sampel	Prolo	Count	12	1	5	1	0	19
		% within Jenis Sampel	63,2%	5,3%	26,3%	5,3%	0,0%	100,0%
		% within Pendidikan	42,9%	100,0%	71,4%	50,0%	0,0%	48,7%
		% of Total	30,8%	2,6%	12,8%	2,6%	0,0%	48,7%
	Normal Saline	Count	16	0	2	1	1	20
		% within Jenis Sampel	80,0%	0,0%	10,0%	5,0%	5,0%	100,0%
		% within Pendidikan	57,1%	0,0%	28,6%	50,0%	100,0%	51,3%
		% of Total	41,0%	0,0%	5,1%	2,6%	2,6%	51,3%
Total		Count	28	1	7	2	1	39
		% within Jenis Sampel	71,8%	2,6%	17,9%	5,1%	2,6%	100,0%
		% within Pendidikan	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%
		% of Total	71,8%	2,6%	17,9%	5,1%	2,6%	100,0%

Crosstab

			Riwayat Penyakit dahulu						Total
			Asam Urat	Dislipidemia	DM Tipe 2	Hipertensi	NHS	Tidak ada	
Jenis Sampel	Prolo	Count	1	1	1	3	3	10	19
		% within Jenis Sampel	5,3%	5,3%	5,3%	15,8%	15,8%	52,6%	100,0%
		% within Riwayat Penyakit dahulu	33,3%	100,0%	25,0%	60,0%	60,0%	47,6%	48,7%
		% of Total	2,6%	2,6%	2,6%	7,7%	7,7%	25,6%	48,7%
	Normal Saline	Count	2	0	3	2	2	11	20
		% within Jenis Sampel	10,0%	0,0%	15,0%	10,0%	10,0%	55,0%	100,0%
		% within Riwayat Penyakit dahulu	66,7%	0,0%	75,0%	40,0%	40,0%	52,4%	51,3%
		% of Total	5,1%	0,0%	7,7%	5,1%	5,1%	28,2%	51,3%
Total		Count	3	1	4	5	5	21	39
		% within Jenis Sampel	7,7%	2,6%	10,3%	12,8%	12,8%	53,8%	100,0%
		% within Riwayat Penyakit dahulu	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%
		% of Total	7,7%	2,6%	10,3%	12,8%	12,8%	53,8%	100,0%

Crosstab

				Kategori IMT			
			underweight	Normal	Risk	Obese I	Total
Jenis Sampel	Prolo	Count	2	8	4	5	19
		% within Jenis Sampel	10,5%	42,1%	21,1%	26,3%	100,0%
		% within Kategori IMT	66,7%	53,3%	57,1%	35,7%	48,7%
		% of Total	5,1%	20,5%	10,3%	12,8%	48,7%
	Normal Saline	Count	1	7	3	9	20
		% within Jenis Sampel	5,0%	35,0%	15,0%	45,0%	100,0%
		% within Kategori IMT	33,3%	46,7%	42,9%	64,3%	51,3%
		% of Total	2,6%	17,9%	7,7%	23,1%	51,3%
Total		Count	3	15	7	14	39
		% within Jenis Sampel	7,7%	38,5%	17,9%	35,9%	100,0%
		% within Kategori IMT	100,0%	100,0%	100,0%	100,0%	100,0%
		% of Total	7,7%	38,5%	17,9%	35,9%	100,0%

2. Tabel Data MMP-1

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	Biomarker	Sphericity Assumed	32.873	2	16.436	4.172	.023
		Greenhouse-Geisser	32.873	1.551	21.199	4.172	.035
		Huynh-Feldt	32.873	1.670	19.690	4.172	.031
		Lower-bound	32.873	1.000	32.873	4.172	.056
	Biomarker * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(Biomarker)	Sphericity Assumed	141.843	36	3.940		
		Greenhouse-Geisser	141.843	27.912	5.082		
		Huynh-Feldt	141.843	30.051	4.720		
		Lower-bound	141.843	18.000	7.880		
Normal Saline	Biomarker	Sphericity Assumed	4.865	2	2.433	.907	.412
		Greenhouse-Geisser	4.865	1.668	2.917	.907	.397
		Huynh-Feldt	4.865	1.809	2.689	.907	.404
		Lower-bound	4.865	1.000	4.865	.907	.353
	Biomarker * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(Biomarker)	Sphericity Assumed	101.896	38	2.681		
		Greenhouse-Geisser	101.896	31.688	3.216		
		Huynh-Feldt	101.896	34.372	2.964		
		Lower-bound	101.896	19.000	5.363		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
MMP1 Mingu 0	Prolo	5.5600	5.13069	19
	Normal Saline	2.8563	1.78688	20
	Total	4.1735	3.99251	39
MMP1 Mingu 6	Prolo	6.3965	3.97865	19
	Normal Saline	3.2321	1.67502	20
	Total	4.7737	3.38656	39
MMP1 Mingu 12	Prolo	7.4172	5.37519	19
	Normal Saline	3.5531	1.86531	20
	Total	5.4356	4.38797	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Intercept	2734.293	1	2734.293	83.254	.000	.692
JenisSampel	307.635	1	307.635	9.367	.004	.202
Error	1215.176	37	32.843			

Pairwise Comparisons

Measure: MEASURE_1

Jenis Sampel	(I) Biomarker	(J) Biomarker	Mean Difference (I-J)	Std. Error	Sig.ᵃ	95% Confidence Interval for Differenceᵃ	
						Lower Bound	Upper Bound
Prolo	1	2	-.836	.679	.701	-2.628	.955
		3	-1.857	.762	.076	-3.869	.155
	2	1	.836	.679	.701	-.955	2.628
		3	-1.021	.450	.108	-2.209	.167
	3	1	1.857	.762	.076	-.155	3.869
		2	1.021	.450	.108	-.167	2.209
Normal Saline	1	2	-.376	.385	1.000	-1.388	.636
		3	-.697	.569	.708	-2.191	.798
	2	1	.376	.385	1.000	-.636	1.388
		3	-.321	.576	1.000	-1.833	1.191
	3	1	.697	.569	.708	-.798	2.191
		2	.321	.576	1.000	-1.191	1.833

Based on estimated marginal means

Mauchly's Test of Sphericityᵃ

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilonᵇ		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	Biomarker	.710	5.817	2	.055	.775	.835	.500
Normal Saline	Biomarker	.801	3.999	2	.135	.834	.905	.500

3. Tabel Data TIMP-1

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	Biomarker	Sphericity Assumed	6051.808	2	3025.904	.747	.481
		Greenhouse-Geisser	6051.808	1.992	3037.578	.747	.480
		Huynh-Feldt	6051.808	2.000	3025.904	.747	.481
		Lower-bound	6051.808	1.000	6051.808	.747	.399
	Biomarker * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(Biomarker)	Sphericity Assumed	145730.306	36	4048.064		
		Greenhouse-Geisser	145730.306	35.862	4063.682		
		Huynh-Feldt	145730.306	36.000	4048.064		
		Lower-bound	145730.306	18.000	8096.128		
Normal Saline	Biomarker	Sphericity Assumed	2568.280	2	1284.140	.567	.572
		Greenhouse-Geisser	2568.280	1.926	1333.394	.567	.566
		Huynh-Feldt	2568.280	2.000	1284.140	.567	.572
		Lower-bound	2568.280	1.000	2568.280	.567	.461
	Biomarker * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(Biomarker)	Sphericity Assumed	86078.113	38	2265.214		
		Greenhouse-Geisser	86078.113	36.596	2352.096		
		Huynh-Feldt	86078.113	38.000	2265.214		
		Lower-bound	86078.113	19.000	4530.427		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
TIMP1 Minggu 0	Prolo	235.8737	135.08959	19
	Normal Saline	173.0194	85.65264	20
	Total	203.6407	115.43627	39
TIMP1 Minggu 6	Prolo	255.0587	142.46167	19
	Normal Saline	188.7759	91.65118	20
	Total	221.0675	122.22955	39
TIMP1 Minggu 12	Prolo	231.2632	108.61959	19
	Normal Saline	183.4320	78.84438	20
	Total	206.7344	96.35076	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Intercept	5217240.013	1	5217240.013	176.862	.000	.827
JenisSampel	101715.834	1	101715.834	3.448	.071	.085
Error	1091463.165	37	29499.004			

Pairwise Comparisons

Measure: MEASURE_1

Jenis Sampel	(I) Biomarker	(J) Biomarker	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
						Lower Bound	Upper Bound
Prolo	1	2	-19.185	20.989	1.000	-74.577	36.207
		3	4.610	19.992	1.000	-48.151	57.372
	2	1	19.185	20.989	1.000	-36.207	74.577
		3	23.796	20.932	.812	-31.446	79.037
	3	1	-4.610	19.992	1.000	-57.372	48.151
		2	-23.796	20.932	.812	-79.037	31.446
Normal Saline	1	2	-15.756	14.609	.883	-54.106	22.593
		3	-10.413	16.425	1.000	-53.530	32.705
	2	1	15.756	14.609	.883	-22.593	54.106
		3	5.344	14.013	1.000	-31.442	42.130
	3	1	10.413	16.425	1.000	-32.705	53.530
		2	-5.344	14.013	1.000	-42.130	31.442

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Greenhouse-Geisser	Huynh-Feldt	Lower-bound
						Epsilon[b]		
Prolo	Biomarker	.996	.066	2	.968	.996	1.000	.500
Normal Saline	Biomarker	.962	.704	2	.703	.963	1.000	.500

130

4. Tabel Data Rasio MMP-1/TIMP-1

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	Biomarker	Sphericity Assumed	.001	2	.000	2.963	.064
		Greenhouse-Geisser	.001	1.707	.001	2.963	.074
		Huynh-Feldt	.001	1.867	.001	2.963	.069
		Lower-bound	.001	1.000	.001	2.963	.102
	Biomarker * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(Biomarker)	Sphericity Assumed	.006	36	.000		
		Greenhouse-Geisser	.006	30.719	.000		
		Huynh-Feldt	.006	33.612	.000		
		Lower-bound	.006	18.000	.000		
Normal Saline	Biomarker	Sphericity Assumed	6.308E-5	2	3.154E-5	.143	.867
		Greenhouse-Geisser	6.308E-5	1.526	4.135E-5	.143	.811
		Huynh-Feldt	6.308E-5	1.632	3.866E-5	.143	.825
		Lower-bound	6.308E-5	1.000	6.308E-5	.143	.709
	Biomarker * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(Biomarker)	Sphericity Assumed	.008	38	.000		
		Greenhouse-Geisser	.008	28.986	.000		
		Huynh-Feldt	.008	31.000	.000		
		Lower-bound	.008	19.000	.000		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
Rasio Biomarker week0	Prolo	.0218	.01555	19
	Normal Saline	.0188	.01449	20
	Total	.0202	.01489	39
Rasio Biomarker week6	Prolo	.0287	.01498	19
	Normal Saline	.0206	.02041	20
	Total	.0246	.01820	39
Rasio Biomarker week12	Prolo	.0315	.00966	19
	Normal Saline	.0212	.01346	20
	Total	.0262	.01273	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Intercept	.066	1	.066	215.792	.000	.854
JenisSampel	.001	1	.001	4.829	.034	.115
Error	.011	37	.000			

Pairwise Comparisons

Measure: MEASURE_1

Jenis Sampel	(I) Biomarker	(J) Biomarker	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
						Lower Bound	Upper Bound
Prolo	1	2	-.007	.005	.514	-.020	.006
		3	-.010	.004	.066	-.020	.001
	2	1	.007	.005	.514	-.006	.020
		3	-.003	.003	1.000	-.012	.006
	3	1	.010	.004	.066	-.001	.020
		2	.003	.003	1.000	-.006	.012
Normal Saline	1	2	-.002	.005	1.000	-.015	.011
		3	-.002	.003	1.000	-.011	.006
	2	1	.002	.005	1.000	-.011	.015
		3	-.001	.006	1.000	-.015	.014
	3	1	.002	.003	1.000	-.006	.011
		2	.001	.006	1.000	-.014	.015

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b]		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	Biomarker	.828	3.207	2	.201	.853	.934	.500
Normal Saline	Biomarker	.689	6.705	2	.035	.763	.816	.500

132

5. Tabel Data NRS Score

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Prolo	NRS	Sphericity Assumed	269.958	4	67.489	88.604	.000	.831
		Greenhouse-Geisser	269.958	2.709	99.656	88.604	.000	.831
		Huynh-Feldt	269.958	3.235	83.445	88.604	.000	.831
		Lower-bound	269.958	1.000	269.958	88.604	.000	.831
	NRS * JenisSampel	Sphericity Assumed	.000	0	.	.	.	.000
		Greenhouse-Geisser	.000	.000	.	.	.	.000
		Huynh-Feldt	.000	.000	.	.	.	.000
		Lower-bound	.000	.000	.	.	.	.000
	Error(NRS)	Sphericity Assumed	54.842	72	.762			
		Greenhouse-Geisser	54.842	48.760	1.125			
		Huynh-Feldt	54.842	58.233	.942			
		Lower-bound	54.842	18.000	3.047			
Normal Saline	NRS	Sphericity Assumed	172.660	4	43.165	56.816	.000	.749
		Greenhouse-Geisser	172.660	2.812	61.407	56.816	.000	.749
		Huynh-Feldt	172.660	3.350	51.536	56.816	.000	.749
		Lower-bound	172.660	1.000	172.660	56.816	.000	.749
	NRS * JenisSampel	Sphericity Assumed	.000	0	.	.	.	.000
		Greenhouse-Geisser	.000	.000	.	.	.	.000
		Huynh-Feldt	.000	.000	.	.	.	.000
		Lower-bound	.000	.000	.	.	.	.000
	Error(NRS)	Sphericity Assumed	57.740	76	.760			
		Greenhouse-Geisser	57.740	53.423	1.081			
		Huynh-Feldt	57.740	63.655	.907			
		Lower-bound	57.740	19.000	3.039			

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
NRS Score	Prolo	5.32	1.003	19
	Normal Saline	5.60	.681	20
	Total	5.46	.854	39
NRS 2	Prolo	3.05	.970	19
	Normal Saline	3.95	1.146	20
	Total	3.51	1.144	39
NRS 4	Prolo	1.58	.838	19
	Normal Saline	2.65	1.137	20
	Total	2.13	1.128	39
NRS 6	Prolo	1.11	.809	19
	Normal Saline	2.00	1.298	20
	Total	1.56	1.165	39
NRS 12	Prolo	.68	.820	19
	Normal Saline	2.40	1.188	20
	Total	1.56	1.334	39

133

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Intercept	1564.775	1	1564.775	760.829	.000	.954
JenisSampel	46.088	1	46.088	22.409	.000	.377
Error	76.097	37	2.057			

Pairwise Comparisons

Measure: MEASURE_1

Jenis Sampel	(I) NRS	(J) NRS	Mean Difference (I-J)	Std. Error	Sig.[b]	95% Confidence Interval for Difference[b]	
						Lower Bound	Upper Bound
Prolo	1	2	2.263[*]	.200	.000	1.624	2.903
		3	3.737[*]	.252	.000	2.932	4.542
		4	4.211[*]	.330	.000	3.157	5.264
		5	4.632[*]	.352	.000	3.506	5.757
	2	1	-2.263[*]	.200	.000	-2.903	-1.624
		3	1.474[*]	.193	.000	.857	2.091
		4	1.947[*]	.291	.000	1.017	2.877
		5	2.368[*]	.335	.000	1.297	3.440
	3	1	-3.737[*]	.252	.000	-4.542	-2.932
		2	-1.474[*]	.193	.000	-2.091	-.857
		4	.474	.246	.704	-.313	1.261
		5	.895	.323	.127	-.139	1.929
	4	1	-4.211[*]	.330	.000	-5.264	-3.157
		2	-1.947[*]	.291	.000	-2.877	-1.017
		3	-.474	.246	.704	-1.261	.313
		5	.421	.257	1.000	-.401	1.243
	5	1	-4.632[*]	.352	.000	-5.757	-3.506
		2	-2.368[*]	.335	.000	-3.440	-1.297
		3	-.895	.323	.127	-1.929	.139
		4	-.421	.257	1.000	-1.243	.401

134

Normal Saline	1	2	1.650*	.221	.000	.949	2.351
		3	2.950*	.246	.000	2.170	3.730
		4	3.600*	.303	.000	2.640	4.560
		5	3.200*	.277	.000	2.320	4.080
	2	1	-1.650*	.221	.000	-2.351	-.949
		3	1.300*	.179	.000	.731	1.869
		4	1.950*	.285	.000	1.044	2.856
		5	1.550*	.359	.004	.411	2.689
	3	1	-2.950*	.246	.000	-3.730	-2.170
		2	-1.300*	.179	.000	-1.869	-.731
		4	.650	.274	.284	-.220	1.520
		5	.250	.307	1.000	-.723	1.223
	4	1	-3.600*	.303	.000	-4.560	-2.640
		2	-1.950*	.285	.000	-2.856	-1.044
		3	-.650	.274	.284	-1.520	.220
		5	-.400	.266	1.000	-1.243	.443
	5	1	-3.200*	.277	.000	-4.080	-2.320
		2	-1.550*	.359	.004	-2.689	-.411
		3	-.250	.307	1.000	-1.223	.723
		4	.400	.266	1.000	-.443	1.243

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b]		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	NRS	.398	15.140	9	.089	.677	.809	.250
Normal Saline	NRS	.345	18.541	9	.030	.703	.838	.250

6. Tabel Data Skor DASH

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	dash	Sphericity Assumed	22773.289	4	5693.322	59.350	.000
		Greenhouse-Geisser	22773.289	2.669	8531.460	59.350	.000
		Huynh-Feldt	22773.289	3.178	7166.446	59.350	.000
		Lower-bound	22773.289	1.000	22773.289	59.350	.000
	dash * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(dash)	Sphericity Assumed	6906.787	72	95.928		
		Greenhouse-Geisser	6906.787	48.048	143.748		
		Huynh-Feldt	6906.787	57.200	120.748		
		Lower-bound	6906.787	18.000	383.710		
Normal Saline	dash	Sphericity Assumed	16009.357	4	4002.339	58.876	.000
		Greenhouse-Geisser	16009.357	3.482	4597.662	58.876	.000
		Huynh-Feldt	16009.357	4.000	4002.339	58.876	.000
		Lower-bound	16009.357	1.000	16009.357	58.876	.000
	dash * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(dash)	Sphericity Assumed	5166.411	76	67.979		
		Greenhouse-Geisser	5166.411	66.159	78.091		
		Huynh-Feldt	5166.411	76.000	67.979		
		Lower-bound	5166.411	19.000	271.916		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
Dash Score Minggu 0	Prolo	52.500	13.6939	19
	Normal Saline	49.905	9.6782	20
	Total	51.169	11.7212	39
Dash Score Minggu 2	Prolo	34.789	12.1632	19
	Normal Saline	35.085	9.0995	20
	Total	34.941	10.5594	39
Dash Score Minggu 4	Prolo	22.847	12.2142	19
	Normal Saline	26.760	9.7270	20
	Total	24.854	11.0408	39
Dash Score Minggu 6	Prolo	13.511	9.7259	19
	Normal Saline	20.280	10.9510	20
	Total	16.982	10.7944	39
Dash Score Minggu 12	Prolo	10.005	10.0566	19
	Normal Saline	13.335	10.7714	20
	Total	11.713	10.4288	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	151709.327	1	151709.327	572.360	.000
JenisSampel	267.324	1	267.324	1.009	.322
Error	9807.195	37	265.059		

Pairwise Comparisons

Measure: MEASURE_1

Jenis Sampel	(I) dash	(J) dash	Mean Difference (I-J)	Std. Error	Sig.[b]	95% Confidence Interval for Difference[b]	
						Lower Bound	Upper Bound
Prolo	1	2	17.711*	3.799	.000	9.730	25.691
		3	29.653*	3.702	.000	21.874	37.431
		4	38.989*	4.015	.000	30.554	47.424
		5	42.495*	4.096	.000	33.889	51.100
	2	1	-17.711*	3.799	.000	-25.691	-9.730
		3	11.942*	2.233	.000	7.250	16.634
		4	21.279*	2.382	.000	16.275	26.283
		5	24.784*	3.075	.000	18.324	31.245
	3	1	-29.653*	3.702	.000	-37.431	-21.874
		2	-11.942*	2.233	.000	-16.634	-7.250
		4	9.337*	2.080	.000	4.968	13.706
		5	12.842*	3.277	.001	5.958	19.726
	4	1	-38.989*	4.015	.000	-47.424	-30.554
		2	-21.279*	2.382	.000	-26.283	-16.275
		3	-9.337*	2.080	.000	-13.706	-4.968
		5	3.505	2.183	.126	-1.080	8.091
	5	1	-42.495*	4.096	.000	-51.100	-33.889
		2	-24.784*	3.075	.000	-31.245	-18.324
		3	-12.842*	3.277	.001	-19.726	-5.958
		4	-3.505	2.183	.126	-8.091	1.080

137

Normal Saline	1	2	14.820[*]	2.576	.000	9.429	20.211
		3	23.145[*]	2.963	.000	16.944	29.346
		4	29.625[*]	2.962	.000	23.425	35.825
		5	36.570[*]	2.868	.000	30.566	42.574
	2	1	-14.820[*]	2.576	.000	-20.211	-9.429
		3	8.325[*]	2.239	.001	3.640	13.010
		4	14.805[*]	2.205	.000	10.189	19.421
		5	21.750[*]	2.808	.000	15.872	27.628
	3	1	-23.145[*]	2.963	.000	-29.346	-16.944
		2	-8.325[*]	2.239	.001	-13.010	-3.640
		4	6.480[*]	2.087	.006	2.113	10.847
		5	13.425[*]	2.529	.000	8.132	18.718
	4	1	-29.625[*]	2.962	.000	-35.825	-23.425
		2	-14.805[*]	2.205	.000	-19.421	-10.189
		3	-6.480[*]	2.087	.006	-10.847	-2.113
		5	6.945[*]	2.656	.017	1.387	12.503
	5	1	-36.570[*]	2.868	.000	-42.574	-30.566
		2	-21.750[*]	2.808	.000	-27.628	-15.872
		3	-13.425[*]	2.529	.000	-18.718	-8.132
		4	-6.945[*]	2.656	.017	-12.503	-1.387

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b]		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	dash	.285	20.583	9	.015	.667	.794	.250
Normal Saline	dash	.733	5.409	9	.798	.871	1.000	.250

7. Tabel Data ROM Abduksi

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	ROM	Sphericity Assumed	12253.684	4	3063.421	7.723	.000
		Greenhouse-Geisser	12253.684	3.355	3652.871	7.723	.000
		Huynh-Feldt	12253.684	4.000	3063.421	7.723	.000
		Lower-bound	12253.684	1.000	12253.684	7.723	.012
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	28558.816	72	396.650		
		Greenhouse-Geisser	28558.816	60.382	472.972		
		Huynh-Feldt	28558.816	72.000	396.650		
		Lower-bound	28558.816	18.000	1586.601		
Normal Saline	ROM	Sphericity Assumed	7814.375	4	1953.594	10.502	.000
		Greenhouse-Geisser	7814.375	3.001	2603.742	10.502	.000
		Huynh-Feldt	7814.375	3.627	2154.628	10.502	.000
		Lower-bound	7814.375	1.000	7814.375	10.502	.004
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	14138.125	76	186.028		
		Greenhouse-Geisser	14138.125	57.023	247.937		
		Huynh-Feldt	14138.125	68.909	205.171		
		Lower-bound	14138.125	19.000	744.112		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
delta abduksi 00	Prolo	125.0000	14.79020	19
	Normal Saline	117.1250	23.99664	20
	Total	120.9615	20.18512	39
delta abduksi 02	Prolo	131.4474	26.50099	19
	Normal Saline	131.5000	25.11028	20
	Total	131.4744	25.45454	39
delta abduksi 04	Prolo	145.5263	26.70023	19
	Normal Saline	137.6250	25.79620	20
	Total	141.4744	26.19963	39
delta abduksi 06	Prolo	151.8421	25.92513	19
	Normal Saline	140.7500	30.14330	20
	Total	146.1538	28.35887	39
Abduksi Minggu 12	Prolo	153.684	26.7105	19
	Normal Saline	140.500	32.9633	20
	Total	146.923	30.4271	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	3684294.872	1	3684294.872	1601.350	.000
JenisSampel	3117.949	1	3117.949	1.355	.252
Error	85127.500	37	2300.743		

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b]		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	ROM	.509	11.092	9	.272	.839	1.000	.250
Normal Saline	ROM	.512	11.655	9	.235	.750	.907	.250

8. Tabel Data ROM Adduksi

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	ROM	Sphericity Assumed	1785.921	4	446.480	2.495	.050
		Greenhouse-Geisser	1785.921	2.058	867.992	2.495	.095
		Huynh-Feldt	1785.921	2.327	767.582	2.495	.087
		Lower-bound	1785.921	1.000	1785.921	2.495	.132
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	12886.579	72	178.980		
		Greenhouse-Geisser	12886.579	37.036	347.952		
		Huynh-Feldt	12886.579	41.880	307.700		
		Lower-bound	12886.579	18.000	715.921		
Normal Saline	ROM	Sphericity Assumed	567.250	4	141.813	.802	.528
		Greenhouse-Geisser	567.250	1.710	331.648	.802	.439
		Huynh-Feldt	567.250	1.863	304.507	.802	.448
		Lower-bound	567.250	1.000	567.250	.802	.382
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	13435.250	76	176.780		
		Greenhouse-Geisser	13435.250	32.498	413.424		
		Huynh-Feldt	13435.250	35.394	379.590		
		Lower-bound	13435.250	19.000	707.118		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
delta adduksi 00	Prolo	47.6316	23.01077	19
	Normal Saline	49.5000	22.08834	20
	Total	48.5897	22.26334	39
delta adduksi 02	Prolo	54.0789	19.27885	19
	Normal Saline	54.2500	13.33032	20
	Total	54.1667	16.27613	39
delta adduksi 04	Prolo	59.0789	10.54786	19
	Normal Saline	54.7500	14.52991	20
	Total	56.8590	12.76970	39
delta adduksi 06	Prolo	59.2105	10.00183	19
	Normal Saline	55.8750	13.33464	20
	Total	57.5000	11.79596	39
Adduksi Minggu 12	Prolo	57.368	10.4574	19
	Normal Saline	56.000	7.7119	20
	Total	56.667	9.0564	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	584659.923	1	584659.923	1284.824	.000
JenisSampel	95.308	1	95.308	.209	.650
Error	16836.872	37	455.051		

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Greenhouse-Geisser	Huynh-Feldt	Lower-bound
						Epsilon[b]		
Prolo	ROM	.120	34.799	9	.000	.514	.582	.250
Normal Saline	ROM	.070	46.421	9	.000	.428	.466	.250

141

9. Tabel Data ROM Fleksi

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	ROM	Sphericity Assumed	8491.711	4	2122.928	6.729	.000
		Greenhouse-Geisser	8491.711	2.793	3040.530	6.729	.001
		Huynh-Feldt	8491.711	3.358	2528.885	6.729	.000
		Lower-bound	8491.711	1.000	8491.711	6.729	.018
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	22715.789	72	315.497		
		Greenhouse-Geisser	22715.789	50.271	451.866		
		Huynh-Feldt	22715.789	60.442	375.828		
		Lower-bound	22715.789	18.000	1261.988		
Normal Saline	ROM	Sphericity Assumed	4800.375	4	1200.094	7.730	.000
		Greenhouse-Geisser	4800.375	2.508	1914.087	7.730	.001
		Huynh-Feldt	4800.375	2.920	1643.913	7.730	.000
		Lower-bound	4800.375	1.000	4800.375	7.730	.012
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	11799.625	76	155.258		
		Greenhouse-Geisser	11799.625	47.650	247.629		
		Huynh-Feldt	11799.625	55.482	212.676		
		Lower-bound	11799.625	19.000	621.033		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
delta fleksi 00	Prolo	129.6053	16.10002	19
	Normal Saline	123.8750	19.64278	20
	Total	126.6667	18.00341	39
delta fleksi 02	Prolo	141.3158	20.35055	19
	Normal Saline	132.0000	18.34609	20
	Total	136.5385	19.66509	39
delta fleksi 04	Prolo	150.6579	24.03473	19
	Normal Saline	137.2500	24.94599	20
	Total	143.7821	25.11730	39
delta fleksi 06	Prolo	156.4474	24.14246	19
	Normal Saline	143.3750	27.80660	20
	Total	149.7436	26.58028	39
Fleksi Minggu 12	Prolo	151.053	29.7012	19
	Normal Saline	140.750	31.4674	20
	Total	145.769	30.6624	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	3854098.570	1	3854098.570	1942.067	.000
JenisSampel	5234.724	1	5234.724	2.638	.113
Error	73427.776	37	1984.534		

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b] Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	ROM	.348	17.329	9	.045	.698	.839	.250
Normal Saline	ROM	.246	24.435	9	.004	.627	.730	.250

10. Tabel Data ROM Ekstensi

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	ROM	Sphericity Assumed	754.868	4	188.717	1.434	.232
		Greenhouse-Geisser	754.868	1.942	388.725	1.434	.252
		Huynh-Feldt	754.868	2.173	347.365	1.434	.251
		Lower-bound	754.868	1.000	754.868	1.434	.247
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	9475.132	72	131.599		
		Greenhouse-Geisser	9475.132	34.954	271.072		
		Huynh-Feldt	9475.132	39.116	242.230		
		Lower-bound	9475.132	18.000	526.396		
Normal Saline	ROM	Sphericity Assumed	866.875	4	216.719	2.018	.100
		Greenhouse-Geisser	866.875	2.370	365.723	2.018	.137
		Huynh-Feldt	866.875	2.730	317.487	2.018	.128
		Lower-bound	866.875	1.000	866.875	2.018	.172
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	8160.625	76	107.377		
		Greenhouse-Geisser	8160.625	45.036	181.203		
		Huynh-Feldt	8160.625	51.878	157.304		
		Lower-bound	8160.625	19.000	429.507		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
delta ektensi 00	Prolo	45.9211	19.00677	19
	Normal Saline	44.7500	18.98580	20
	Total	45.3205	18.75377	39
delta ekstensi 02	Prolo	47.3684	10.05104	19
	Normal Saline	45.3750	10.64607	20
	Total	46.3462	10.27334	39
delta ekstensi 04	Prolo	50.2632	10.37139	19
	Normal Saline	50.1250	11.16488	20
	Total	50.1923	10.64352	39
delta ekstensi 06	Prolo	52.5000	9.20447	19
	Normal Saline	52.6250	9.19364	20
	Total	52.5641	9.07728	39
Ekstensi Minggu 12	Prolo	53.158	11.8099	19
	Normal Saline	47.750	10.5724	20
	Total	50.385	11.3778	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	467573.130	1	467573.130	1471.441	.000
JenisSampel	143.642	1	143.642	.452	.506
Error	11757.319	37	317.765		

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b] Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	ROM	.089	39.727	9	.000	.485	.543	.250
Normal Saline	ROM	.202	27.895	9	.001	.593	.683	.250

144

11. Tabel Data ROM Eksternal Rotasi

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	ROM	Sphericity Assumed	2717.500	4	679.375	3.681	.009
		Greenhouse-Geisser	2717.500	2.396	1134.007	3.681	.027
		Huynh-Feldt	2717.500	2.790	974.084	3.681	.020
		Lower-bound	2717.500	1.000	2717.500	3.681	.071
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	13290.000	72	184.583		
		Greenhouse-Geisser	13290.000	43.135	308.105		
		Huynh-Feldt	13290.000	50.216	264.655		
		Lower-bound	13290.000	18.000	738.333		
Normal Saline	ROM	Sphericity Assumed	4929.625	4	1232.406	5.043	.001
		Greenhouse-Geisser	4929.625	2.780	1773.288	5.043	.005
		Huynh-Feldt	4929.625	3.304	1491.806	5.043	.003
		Lower-bound	4929.625	1.000	4929.625	5.043	.037
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	18572.875	76	244.380		
		Greenhouse-Geisser	18572.875	52.819	351.634		
		Huynh-Feldt	18572.875	62.785	295.818		
		Lower-bound	18572.875	19.000	977.520		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
delta eksternalRot 00	Prolo	61.0526	23.79478	19
	Normal Saline	53.1250	25.33817	20
	Total	56.9872	24.60330	39
delta ekternal Rot 02	Prolo	69.3421	16.70500	19
	Normal Saline	61.5000	21.90590	20
	Total	65.3205	19.69487	39
delta eksternal rotasi 04	Prolo	72.2368	13.53736	19
	Normal Saline	65.3750	15.69183	20
	Total	68.7179	14.89957	39
delta eksternal Rot 06	Prolo	75.9211	12.78048	19
	Normal Saline	72.3750	11.96142	20
	Total	74.1026	12.33426	39
Eksternal Rotasi Minggu 12	Prolo	75.000	12.9099	19
	Normal Saline	71.250	14.1305	20
	Total	73.077	13.5051	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	893622.703	1	893622.703	1317.451	.000
JenisSampel	1745.395	1	1745.395	2.573	.117
Error	25096.977	37	678.297		

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b]		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	ROM	.273	21.286	9	.012	.599	.697	.250
Normal Saline	ROM	.285	21.876	9	.010	.695	.826	.250

12. Tabel Data ROM Internal Rotasi

Tests of Within-Subjects Effects

Measure: MEASURE_1

Jenis Sampel	Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Prolo	ROM	Sphericity Assumed	5725.658	4	1431.414	5.147	.001
		Greenhouse-Geisser	5725.658	2.383	2402.849	5.147	.007
		Huynh-Feldt	5725.658	2.771	2066.312	5.147	.004
		Lower-bound	5725.658	1.000	5725.658	5.147	.036
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	20024.342	72	278.116		
		Greenhouse-Geisser	20024.342	42.892	466.860		
		Huynh-Feldt	20024.342	49.877	401.473		
		Lower-bound	20024.342	18.000	1112.463		
Normal Saline	ROM	Sphericity Assumed	1059.625	4	264.906	1.617	.179
		Greenhouse-Geisser	1059.625	3.180	333.239	1.617	.192
		Huynh-Feldt	1059.625	3.893	272.155	1.617	.180
		Lower-bound	1059.625	1.000	1059.625	1.617	.219
	ROM * JenisSampel	Sphericity Assumed	.000	0	.	.	.
		Greenhouse-Geisser	.000	.000	.	.	.
		Huynh-Feldt	.000	.000	.	.	.
		Lower-bound	.000	.000	.	.	.
	Error(ROM)	Sphericity Assumed	12452.875	76	163.854		
		Greenhouse-Geisser	12452.875	60.416	206.120		
		Huynh-Feldt	12452.875	73.976	168.337		
		Lower-bound	12452.875	19.000	655.414		

Descriptive Statistics

	Jenis Sampel	Mean	Std. Deviation	N
delta internalRot 00	Prolo	43.6842	20.05839	19
	Normal Saline	46.7500	26.03262	20
	Total	45.2564	23.06167	39
delta Internal Rot 02	Prolo	48.8158	23.00918	19
	Normal Saline	54.6250	22.24675	20
	Total	51.7949	22.51424	39
delta Internal rotasi 04	Prolo	52.5000	25.98076	19
	Normal Saline	51.5000	21.46601	20
	Total	51.9872	23.46035	39
delta Internal Rot 06	Prolo	56.8421	21.98235	19
	Normal Saline	55.3750	23.62362	20
	Total	56.0897	22.54962	39
Internal Rotasi Minggu 12	Prolo	66.579	21.6700	19
	Normal Saline	55.000	22.7689	20
	Total	60.641	22.7162	39

Tests of Between-Subjects Effects

Measure: MEASURE_1

Transformed Variable: Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Intercept	550852.108	1	550852.108	313.161	.000
JenisSampel	52.108	1	52.108	.030	.864
Error	65083.276	37	1759.007		

Mauchly's Test of Sphericity[a]

Measure: MEASURE_1

Jenis Sampel	Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[b]		
						Greenhouse-Geisser	Huynh-Feldt	Lower-bound
Prolo	ROM	.188	27.443	9	.001	.596	.693	.250
Normal Saline	ROM	.521	11.349	9	.255	.795	.973	.250

147